Bioavailability of LY03004 and Risperdal® Consta®

- To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25
mg following multiple intramuscular injections at steady-state;

- To evaluate the safety and tolerability of LY03004 following repeated intramuscular
injections

- To evaluate the preliminary efficacy of LY03004 following repeated intramuscular
injections

Inclusion Criteria:

1. Male or female patients aged 18 to 65 years old

2. Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder
based on the Mini-International Neuropsychiatric Interview (MINI)

3. Patients must be clinically stable on antipsychotic medications other than
risperidone or paliperidone or clozapine for at least 4 weeks prior to screening,
based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS)
total score less than or equal 70 at Screening Visit

4. Patients with a Body Mass Index in range of 18.0 to 35.0

5. Patients with an Informed Consent Form signed by the patient or legally authorized
representative

Exclusion Criteria:

1. Patients with a mental disorders other than schizophrenia or schizoaffective
disorder, according to the DSM-IV-TR

2. Patients who received oral risperidone or paliperidone or clozapine within 14 days
prior to screening, or Risperdal® Consta® within 100 days prior to screening or
paliperidone palmitate within 10 months prior to screening

3. Patients with neuroleptic malignant syndrome or physical fatigue associated with
dehydration or malnutrition

4. Patients who pose a significant risk of a suicide attempt based on history,
investigator's judgment or have answered "yes" to the questions 4 or 5 for current or
past 30 days on the screening form of the Columbia Suicide Severity Rating Scale
(C-SSRS)

5. Patients with a history of sensitivity to akathisia and other EPS, especially with
previous use of risperidone or paliperidone

6. Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater
than or equal to 7%

7. Patients with a history of or currently having epilepsy or convulsion disorders

8. Patients who have had electroconvulsive therapy within the past 2 months prior to
screening

9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2
weeks prior to screening

10. Patients with a history of allergic reaction to risperidone or to the excipients of
LY03004

11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the
exception of caffeine or nicotine in the past 6 months prior to screening

12. Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular
disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis

13. Patients who are currently taking medications with primarily CNS activities such as
antidepressants, mood stabilizers or anticonvulsants

14. Patients who have participated in a clinical trial of another investigational drug
within 30 days prior to screening

15. Female patients who are pregnant or are breastfeeding or are of childbearing
potential without adequate use of contraception

16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or
other medical condition or laboratory abnormality, which in the judgment of the
investigator would interfere with the subject's ability to participate in the study